Category: Kips Bay Medical Inc.
Kips Bay Medical says it's laying off nearly 40% of its workforce as it restructures to focus on its eSVS mesh for bypass grafts.
Top execs from Haemonetics, Kips Bay and others open up about their biggest regrets, debate market pressures facing the medtech industry and offer advice for young entrepreneurs.
A group of medtech insiders gathered in Boston last night to talk shop, share stories and glean insight from some of the industry's brightest minds at MassDevice's DeviceTalks East conference.
An FDA inspection clears a Plainsboro, N.J. plant that triggered a warning letter for Integra LifeSciences, sending share prices up today.
Integra LifeSciences (NSDQ:IART) shares are up today after the medical device company revealed that FDA inspectors yesterday cleared a New Jersey plant that was the subject of a 2011 warning letter.
Kips Bay reports widening losses and shrinking sales for its 4th quarter, but the FDA's decision to allow full enrollment in the U.S. arm of the company's feasibility trial is an important turnaround for the device maker.
Medical device maker Kips Bay Medical (NSDQ:KIPS) saw widening losses and sinking sales during its most recent quarter, but the company marked an important win with FDA approval to complete full enrollment in the U.S. arm of a feasibility study.
Cardiovascular Systems prices an offering of 2 million shares at $17.60 apiece, saying it expects to net about $33 million from the deal for "working capital and general corporate purposes," likely including its ORBIT II atherectomy trial.
Cardiovascular Systems (NSDQ:CSII) priced a public offering of some 2 million shares of CSII stock at $17.60 apiece, saying it expects to net about $33 million from the deal.
Holaira says it raised $10 million from existing investors for its lung denervation system to treat chronic obstructive pulmonary disease.
Medical device company Holaira said it drummed up $10 million, changed its name and moved its headquarters.
Formerly known as Innovative Pulmonary Solutions, Holaira said it plans to use the Series C round to develop its minimally invasive devices to treat obstructive lung disease. All of Holaira's existing backers participated, namely Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners, and Versant Ventures.
Echo Therapeutics aims to raise some $10 million from a public offering of 10.3 million shares of stock at 75¢ apiece.
Echo Therapeutics (NSDQ:ECTE) priced its public stock offering at 75¢ per share, saying it expects to raise about $10 million in gross proceeds.
The 13.3 million-share offering includes a 45-day over-allotment option for bookrunner Aegis Capital for another 2 million shares.